Epinephrine is the known treatment for anaphylaxis. The way that epinephrine is administered is through injection. That may soon change. ARS Pharmaceuticals has announced that the United States Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray currently in clinical development. Because time is of the essence when an anaphylaxis attack occurs, many believe, as does ASR, an epinephrine nasal spray can be an effective replacement treatment of autoinjectors. A fear of needles or apprehension of operating an auto-injector has been sighted as one of the reasons for the desire for an epinephrine nasal spray.
Patent Approval Covers Fast-acting Decreased Dosage Level for Intranasal Administration for type 1 Allergic Reaction
By News Wire ~ 3rd Party Press Release
July 13th, 2020
SAN DIEGO –
ARS Pharmaceuticals today announced that on June 16, 2020, the United States Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray currently in clinical development. This dosage is significantly lower than other reported investigational intranasal epinephrine projects in development and thus helps protect against possible accidental overdose risk during a severe allergic reaction. This follows a patent approved last year covering the composition of matter of ARS-1. ARS Pharmaceuticals is dedicated to putting patients first and these ARS-1 innovations are an important step for those with severe allergic reactions to get lifesaving, pain free treatment.